[
    {
        "Drug": "sulfomethoxazole+trimethoprim",
        "Abv": "TMP-SMX",
        "Forms": " powder for IV, tablet (co-formulated with TMP)",
        "Brand": "Bactrim™ and Septra™",
        "AntiBiotic_Class": "sulfonamides - diaminopyrimidine",
        "Star_Features": "resistance development to TMP-SMX is limited by the 2 drugs acting synergistically blocking sequential steps in folic acid synthesis \nresistance in streptococcus (e.g., do not use for strep throat), but effective against MSSA and many CA-MRSA strains ",
        "Structural_Features": "",
        "MOA": "sulfonamides are bacteriostatic agents that compete with PABA \n(competitive inhibitor) and folate synthesis inhibitor of dihydropteroate synthase",
        "Contraindications": " patients <2 mo.; megaloblastic anemia due to folate deficiency;",
        "Important_Attribute": "uropathogens, staph, CA-MRSA",
        "Spectrum": "MSSA, CA-MRSA, PEK, +ESBL",
        "Cellular_Target": "sulfamethoxazole- dihydropteroate synthase \\n trimethoprim- dihydrofolate reductase",
        "Cell_Structure_affected": "Sulfamethoxazole- folic acid synthesis \\nTrimethoprim",
        "Adverse_Reactions:": "hypersensitivity-Stevens Johnson syndrome  “sulfa drug”\ncrystalluria – crystal formation in the kidneys causing organ damage\nanemia = decreased RBC\n rash*, pruritus*,  ",
        "Pharmacodynamics": "",
        "Pronunciation": "SUL-fa-meth-OX-a-zole-and-trye-METH-oh-prim",
        "Chem_Url": "https://upload.wikimedia.org/wikipedia/commons/thumb/e/e8/Trimethoprim_and_sulfamethoxazole.svg/300px-Trimethoprim_and_sulfamethoxazole.svg.png"
    },
    {
        "Drug": "nitrofurantoin",
        "Abv": "NIT",
        "Forms": "capsules, suspension",
        "Brand": "Macrobid™ (macrocrystal formulation better tolerated in GI), Furadantin™, Macrodantin™",
        "AntiBiotic_Class": "nitrofurans",
        "Star_Features": "urinary pathogens",
        "Structural_Features": "prodrugs",
        "MOA": "activity depends on a bacterial nitroreductase reduction of the nitro group \n\\n the radical product reacts with O2 forming O2\\n that causes DNA damage.",
        "Contraindications": "",
        "Important_Attribute": "uropathogens, VRE",
        "Spectrum": "Enterococcus, + VRE, PEK, +ESBL",
        "Cellular_Target": "nucleic acid ",
        "Cell_Structure_affected": "DNA damage",
        "Adverse_Reactions:": "GI irritant; causes urine to turn dark brown",
        "Pharmacodynamics": "",
        "Pronunciation": "NYE-troe-fue-RAN-toin ",
        "Chem_Url": "https://upload.wikimedia.org/wikipedia/commons/c/c4/Nitrofurantoin.svg"
    },
    {
        "Drug": "fosfomycin ",
        "Abv": "FOF",
        "Forms": "granules",
        "Brand": "Monurol",
        "AntiBiotic_Class": "Phosphonic acids",
        "Star_Features": "urinary bacteria\\nachieves very high urinary concentration (>2000 mg/mL) minimizing resistance development",
        "Structural_Features": "",
        "MOA": "",
        "Contraindications": "",
        "Important_Attribute": "uropathogens, MRSA, VRE",
        "Spectrum": "MSSA, MRSA, Enterococcus, + VRE, PEK, +ESBL",
        "Cellular_Target": "NAM synthesis",
        "Cell_Structure_affected": " cell wall synthesis",
        "Adverse_Reactions:": "",
        "Pharmacodynamics": "",
        "Pronunciation": "FOS-foe-MYE-sin",
        "Chem_Url": "https://upload.wikimedia.org/wikipedia/commons/thumb/9/9d/Fosfomycin.svg/188px-Fosfomycin.svg.png"
    },
    {
        "Drug": "metronidazole",
        "Abv": "MTZ",
        "Forms": "tablets, capsule, topical, powder, suppository",
        "Brand": "Flagyl™ (oral); Metrogel™, Metrocream™ (topicals)",
        "AntiBiotic_Class": "Nitroimidazoles",
        "Star_Features": "",
        "Structural_Features": "",
        "MOA": "prodrugs that exert their toxic effect in bacteria via e reduction of the nitro group by bacterial nitroreductase (required for prodrug activation) \\n nitro radical interacts w/ the DNA causing the strand break",
        "Contraindications": "alcohol is contraindicated",
        "Important_Attribute": "anaerobes, ≈ C. diff resistance increasing",
        "Spectrum": "Anaerobes, ≈ C. Diff",
        "Cellular_Target": "nucleic acid",
        "Cell_Structure_affected": "DNA damage",
        "Adverse_Reactions:": "not well tolerated by GI system (severe nausea)  \n\\ncan induce vaginal candidiasis requiring antifungal treatment \\n disulfiram reaction",
        "Pharmacodynamics": "",
        "Pronunciation": "me-troe-NI-da-zole",
        "Chem_Url": "https://upload.wikimedia.org/wikipedia/commons/thumb/f/f1/Metronidazole.svg/240px-Metronidazole.svg.png"
    },
    {
        "Drug": "ciprofloxacin",
        "Abv": "CIP",
        "Forms": "vial, tablets, capsules, solution, ointment",
        "Brand": "Cipro™ is rapidly eliminated in urine \\nCipro XR (extended release) tablets -  taken once daily",
        "AntiBiotic_Class": "2nd Generation Quinolones ",
        "Star_Features": "S. pneumoniae, \nenterococcus = resistant ",
        "Structural_Features": "fluorine atom – located at the C-6 position; adds lipophilicity aiding in \nouter membrane penetration and increasing binding affinity to mutated \nDNA gyrase \n\\npiperazine ring – located at the C-7 position; increases bioactivity \nspectrum including Gram (+) bacteria; increases half-life making it useful for systemic infection",
        "MOA": "Quinolones are bactericidal agents that inhibit DNA gyrase (topoisomerase) inhibition makes a bacterium’s DNA inaccessible (for replication, protein synthesis) and leads to cell death ",
        "Contraindications": "",
        "Important_Attribute": "2nd gen. – SPACE, unreliable for strep",
        "Spectrum": "MSSA, PEK, PIDDLY, SACE, Pseudomonas, Atypicals",
        "Cellular_Target": "DNA gyrase ",
        "Cell_Structure_affected": "DNA synthesis",
        "Adverse_Reactions:": "tendonitis, phototoxicity, QT prolongation",
        "Pharmacodynamics": "",
        "Pronunciation": "SIP-roe-FLOX-a-sin",
        "Chem_Url": "https://upload.wikimedia.org/wikipedia/commons/thumb/7/7d/Ciprofloxacin.svg/300px-Ciprofloxacin.svg.png"
    },
    {
        "Drug": "levofloxacin",
        "Abv": "LFN",
        "Forms": "powder, tablets, solution",
        "Brand": "Levaquin",
        "AntiBiotic_Class": "3rd Generation Quinolones ",
        "Star_Features": "the S-enantiomer of ofloxacin and is 2x as potent • due to its broad activity spectrum, often given empirically",
        "Structural_Features": "characterized by an additional C-8 substituent to FQ ring \n\\ndeveloped becas S. pneumoniae (pneumococcus) and expanded atypical coverage  \n\\nused for bacterial causes of community-acquired pneumonia (CAP):",
        "MOA": "",
        "Contraindications": "",
        "Important_Attribute": "3rd gen. SPACE",
        "Spectrum": "MSSA, Strep, S. pneumo, PEK, PIDDLY, SACE, Pseudomonas, Atypicals",
        "Cellular_Target": "DNA gyrase ",
        "Cell_Structure_affected": "DNA synthesis",
        "Adverse_Reactions:": "tendonitis, phototoxicity, QT prolongation",
        "Pharmacodynamics": "",
        "Pronunciation": "LEE-voe-FLOX-a-si",
        "Chem_Url": "https://upload.wikimedia.org/wikipedia/commons/thumb/8/83/Levofloxacin_skeletal.svg/375px-Levofloxacin_skeletal.svg.png"
    },
    {
        "Drug": "moxifloxacin",
        "Abv": "MFN",
        "Forms": "powder, tablets, solution",
        "Brand": "Avelox™ (oral, IV), Vigamox™ (eye drop)",
        "AntiBiotic_Class": "4th Generation Quinolones ",
        "Star_Features": "only FQ that covers anaerobes\n\\nprimarily eliminated in feces (hepatic) \n• low urinary excretion → only FQ not used to treat UTIs \n• no dosage adjustment is necessary in patients with renal impairment ",
        "Structural_Features": "",
        "MOA": "",
        "Contraindications": "",
        "Important_Attribute": "4th gen. anaerobes",
        "Spectrum": "MSSA, Strep, S. pneumo, PEK, PIDDLY, SACE, Anaerobes, Atypicals",
        "Cellular_Target": "DNA gyrase ",
        "Cell_Structure_affected": "DNA synthesis",
        "Adverse_Reactions:": "tendonitis, phototoxicity, QT prolongation",
        "Pharmacodynamics": "",
        "Pronunciation": "mox-ee-FLOX-a-sin",
        "Chem_Url": "https://upload.wikimedia.org/wikipedia/commons/thumb/e/e9/Moxifloxacin.svg/330px-Moxifloxacin.svg.png"
    },
    {
        "Drug": "delafloxacin",
        "Abv": "",
        "Forms": "",
        "Brand": "Baxdela",
        "AntiBiotic_Class": "Anionic Quinolones",
        "Star_Features": "for SSSI and covers MRSA and Pseudomonas",
        "Structural_Features": "newest FQ class with only 1 ionizable group (COOH); all previous approved FQ are zwitterionic",
        "MOA": "",
        "Contraindications": "",
        "Important_Attribute": "MRSA + Pseudomonas",
        "Spectrum": "MSSA, MRSA, Strep, S. pneumo, PEK, PIDDLY, SACE, Pseudomonas",
        "Cellular_Target": "",
        "Cell_Structure_affected": "",
        "Adverse_Reactions:": "",
        "Pharmacodynamics": "",
        "Pronunciation": "del-a-FLOX-a-sin",
        "Chem_Url": "https://upload.wikimedia.org/wikipedia/commons/thumb/1/19/Delafloxacin.svg/375px-Delafloxacin.svg.png"
    },
    {
        "Drug": "penicillin G",
        "Abv": "PEN",
        "Forms": "powder",
        "Brand": "Pfizerpen™, benzathine, or procaine salt",
        "AntiBiotic_Class": "B-lactam",
        "Star_Features": "poor oral absorption; rapidly excreted\\nunstable to stomach acid = IV (Na+/K+ salt) or IM (procaine/benzathine salt) injection used",
        "Structural_Features": "",
        "MOA": "",
        "Contraindications": "probenecid (for gout) increases and prolongs serum of B-lactam antibiotics\\nB-lactam antibiotics are incompatible with aminoglycosides;  \n\\n B-lactam antibiotics can interfere with the enterohepatic circulation of oral estrogens  resulting in \nsubtherapeutic estrogen levels ",
        "Important_Attribute": "Group 1-2 - narrow spectrum",
        "Spectrum": "Strep, S. pneumo",
        "Cellular_Target": "",
        "Cell_Structure_affected": "",
        "Adverse_Reactions:": "most serious ADR is an immediate IgE-mediated anaphylaxis (Type I  hypersensitivity)\nor IV (delayed) hypersensitivity) reaction can cause Coombs + hemolytic anemia,: \\npenicillins may also react with proteins on the surface of RBC cell membrane; once attached, the immune system begins \ndestroying the RBCs that could lead to anemia (i.e., Coombs + hemolytic anemia).\n\\n",
        "Pharmacodynamics": "excreted in urine",
        "Pronunciation": "pen-i-SIL-in G",
        "Chem_Url": "https://upload.wikimedia.org/wikipedia/commons/thumb/6/67/Benzylpenicillin.svg/375px-Benzylpenicillin.svg.png"
    },
    {
        "Drug": "penicillin VK",
        "Abv": "Pen VK",
        "Forms": "tablets, powder",
        "Brand": "",
        "AntiBiotic_Class": "B-lactam",
        "Star_Features": "more acid-stable than PEN for oral dosing",
        "Structural_Features": "",
        "MOA": "",
        "Contraindications": "",
        "Important_Attribute": "Group 1-2 - narrow spectrum",
        "Spectrum": "Strep, S. pneumo, Oral = Anaerobes",
        "Cellular_Target": "",
        "Cell_Structure_affected": "",
        "Adverse_Reactions:": "",
        "Pharmacodynamics": "excreted in urine",
        "Pronunciation": "pen-i-SIL-in V K",
        "Chem_Url": "https://upload.wikimedia.org/wikipedia/commons/thumb/4/43/Penicillin-V-2D-skeletal.svg/330px-Penicillin-V-2D-skeletal.svg.png"
    },
    {
        "Drug": "oxacillin",
        "Abv": "OXA",
        "Forms": "IV or IM",
        "Brand": "Bactocill™, Prostaphlin™",
        "AntiBiotic_Class": "B-lactam Group III Penicillins.",
        "Star_Features": "short half-life (0.5 hrs); blood levels may be prolonged by concurrent administration of \nprobenecid which blocks the renal tubular secretion of penicillins",
        "Structural_Features": "resistance to B-lactamase hydrolysis is caused by poor binding (steric hindrance) due to the C-6 sidechain substituents: ",
        "MOA": "",
        "Contraindications": "",
        "Important_Attribute": "Group 3 – staph only",
        "Spectrum": "MSSA, Strep, S. pneumo, Oral = Anaerobes",
        "Cellular_Target": "",
        "Cell_Structure_affected": "",
        "Adverse_Reactions:": "",
        "Pharmacodynamics": "excreted in urine",
        "Pronunciation": "ox-a-SIL-in",
        "Chem_Url": "https://upload.wikimedia.org/wikipedia/commons/thumb/a/ae/Oxacillin_skeletal.svg/330px-Oxacillin_skeletal.svg.png"
    },
    {
        "Drug": "nafcillin",
        "Abv": "NAF",
        "Forms": "oral or IV (preferred)",
        "Brand": "Nallpen",
        "AntiBiotic_Class": "B-lactam Group III Penicillins.",
        "Star_Features": "",
        "Structural_Features": "",
        "MOA": "",
        "Contraindications": "",
        "Important_Attribute": "Group 3 – staph only",
        "Spectrum": "MSSA, Strep, S. pneumo",
        "Cellular_Target": "",
        "Cell_Structure_affected": "",
        "Adverse_Reactions:": "",
        "Pharmacodynamics": "all penicillins except NAF are excreted in urine \\n eliminated primarily feces",
        "Pronunciation": "naf-SIL-in",
        "Chem_Url": "https://upload.wikimedia.org/wikipedia/commons/thumb/8/82/Nafcillin.svg/330px-Nafcillin.svg.png"
    },
    {
        "Drug": "dicloxacillin",
        "Abv": "DIC",
        "Forms": "capsule",
        "Brand": "Dynapen™",
        "AntiBiotic_Class": "B-lactam Group III Penicillins.",
        "Star_Features": "erratic absorption",
        "Structural_Features": "",
        "MOA": "",
        "Contraindications": "",
        "Important_Attribute": "Group 3 – staph only",
        "Spectrum": "MSSA, Strep, S. pneumo",
        "Cellular_Target": "",
        "Cell_Structure_affected": "",
        "Adverse_Reactions:": "metallic taste and belching",
        "Pharmacodynamics": "excreted in urine",
        "Pronunciation": "dye-klox-a-SIL-in",
        "Chem_Url": "https://upload.wikimedia.org/wikipedia/commons/thumb/f/fd/Dicloxacillin.svg/330px-Dicloxacillin.svg.png"
    },
    {
        "Drug": "ampicillin",
        "Abv": "AMP",
        "Forms": "powder, capsules, suspension",
        "Brand": "Omnipen™, UNASYN™ (with sulbactam)",
        "AntiBiotic_Class": "B-lactam Group IV Penicillins. (aminopenicillins) ",
        "Star_Features": "often given with the B-lactamase inhibitor sulbactam \\n synergy with aminoglycosides for meningitis infections (e.g., listeriosis)",
        "Structural_Features": "",
        "MOA": "",
        "Contraindications": "higher risk of rash in patients with mononucleosis",
        "Important_Attribute": "Group 4 - no MSSA, some ≈ PIDDLY",
        "Spectrum": "Strep, S. pneumo, Enterococcus, + VRE, PEK, ≈ PIDDLY, Anaerobes",
        "Cellular_Target": "",
        "Cell_Structure_affected": "",
        "Adverse_Reactions:": "diarrhea common due to incomplete absorption (kills intestinal microflora) → watch for CDAD  \\n rashes occur more often with AMP and AMX than with other penicillins.",
        "Pharmacodynamics": "",
        "Pronunciation": "am-pi-SIL-in",
        "Chem_Url": "https://upload.wikimedia.org/wikipedia/commons/thumb/b/b6/Ampicillin_structure.svg/300px-Ampicillin_structure.svg.png"
    },
    {
        "Drug": "amoxicillin ",
        "Abv": "AMX",
        "Forms": "tablets, suspension",
        "Brand": "Amoxil™ (oral suspension); Augmentin™ (w/ clavulanic acid)",
        "AntiBiotic_Class": "B-lactam Group IV Penicillins. (aminopenicillins) ",
        "Star_Features": "better oral bioavailability than ampicillin - less diarrhea b/c more \ncomplete absorption \n\\n B-lactamase susceptible; often given with the B-lactamase inhibitor clavulanic acid",
        "Structural_Features": "",
        "MOA": "",
        "Contraindications": "higher risk of rash in patients with mononucleosis",
        "Important_Attribute": "Group 4 - no MSSA, some ≈ PIDDLY",
        "Spectrum": "Strep, S. pneumo, Enterococcus, + VRE, PEK, ≈ PIDDLY, Anaerobes",
        "Cellular_Target": "",
        "Cell_Structure_affected": "",
        "Adverse_Reactions:": "diarrhea (due to clavulanic acid) \\n rashes occur more often with AMP and AMX than with other penicillins.",
        "Pharmacodynamics": "",
        "Pronunciation": "a-mox-i-SIL-in",
        "Chem_Url": "https://upload.wikimedia.org/wikipedia/commons/thumb/0/02/Amoxicillin.svg/330px-Amoxicillin.svg.png"
    },
    {
        "Drug": "Ampicillin/sulbactam",
        "Abv": "",
        "Forms": "",
        "Brand": "",
        "AntiBiotic_Class": "",
        "Star_Features": "",
        "Structural_Features": "",
        "MOA": "",
        "Contraindications": "",
        "Important_Attribute": "Group 4 – MSSA, Bacteriodes",
        "Spectrum": "MSSA, Strep, S. pneumo, Enterococcus, + VRE, PEK, ≈ PIDDLY, Anaerobes",
        "Cellular_Target": "",
        "Cell_Structure_affected": "",
        "Adverse_Reactions:": "",
        "Pharmacodynamics": "",
        "Pronunciation": "am-pi-SIL-in sul-BAK-tam",
        "Chem_Url": "https://upload.wikimedia.org/wikipedia/commons/thumb/6/64/Sultamicillin_schematic.svg/330px-Sultamicillin_schematic.svg.png"
    },
    {
        "Drug": "Amoxicillin/clavulanic acid",
        "Abv": "",
        "Forms": "",
        "Brand": "",
        "AntiBiotic_Class": "",
        "Star_Features": "",
        "Structural_Features": "",
        "MOA": "",
        "Contraindications": "",
        "Important_Attribute": "Group 4 – MSSA, Bacteriodes",
        "Spectrum": "MSSA, Strep, S. pneumo, Enterococcus, + VRE, PEK, ≈ PIDDLY, Anaerobes",
        "Cellular_Target": "",
        "Cell_Structure_affected": "",
        "Adverse_Reactions:": "",
        "Pharmacodynamics": "",
        "Pronunciation": "a-mox-i-SIL-in klav-yoo-LAN-ik acid",
        "Chem_Url": "https://upload.wikimedia.org/wikipedia/commons/thumb/4/42/Amoxicillin_and_clavulanic_acid.svg/330px-Amoxicillin_and_clavulanic_acid.svg.png"
    },
    {
        "Drug": "Ticarcillin/clavulanic acid",
        "Abv": "TIC",
        "Forms": "powder for IV/IM dosing (Na salt)",
        "Brand": "Timentin™ (w/ clavulanic acid)",
        "AntiBiotic_Class": "",
        "Star_Features": "disodium formulated (precaution in pts with restricted Na intake \\n co-formulated with the -lactamase inhibitor clavulanic acid ",
        "Structural_Features": "",
        "MOA": "",
        "Contraindications": "",
        "Important_Attribute": "Group 5 - SPACE",
        "Spectrum": "MSSA, Strep, S. pneumo, Enterococcus, + VRE, PEK, PIDDLY, SACE, Pseudomonas, Anaerobes",
        "Cellular_Target": "",
        "Cell_Structure_affected": "",
        "Adverse_Reactions:": "",
        "Pharmacodynamics": "",
        "Pronunciation": "tye-KAR-sil-in klav-yoo-LAN-ik acid",
        "Chem_Url": "https://upload.wikimedia.org/wikipedia/commons/thumb/b/b3/Ticarcillin.svg/330px-Ticarcillin.svg.png"
    }
]
